MacroGenics | MGNX - Operating Expenses


MacroGenics reported $21.2M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Genmab DKK 798M 235M Dec/2025
Geron USD 52.07M 6.73M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 15.77B 2.4B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Xencor USD 82.38M 513K Mar/2026